Report cover image

Cutaneous and Systemic Leishmaniasis

Published Jun 01, 2025
Length 473 Pages
SKU # GJOB20090187

Description

Global Cut-Off Tools Market to Reach US$3.9 Billion by 2030

The global market for Cut-Off Tools estimated at US$3.3 Billion in the year 2024, is expected to reach US$3.9 Billion by 2030, growing at a CAGR of 3.0% over the analysis period 2024-2030. Electric Technology, one of the segments analyzed in the report, is expected to record a 2.3% CAGR and reach US$2.5 Billion by the end of the analysis period. Growth in the Pneumatic Technology segment is estimated at 4.4% CAGR over the analysis period.

The U.S. Market is Estimated at US$889.9 Million While China is Forecast to Grow at 5.6% CAGR

The Cut-Off Tools market in the U.S. is estimated at US$889.9 Million in the year 2024. China, the world`s second largest economy, is forecast to reach a projected market size of US$760.8 Million by the year 2030 trailing a CAGR of 5.6% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 1.2% and 2.3% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 1.7% CAGR.

Global Cut-Off Tools Market – Key Trends & Drivers Summarized

Why Are Cut-Off Tools Essential in Industrial and Precision Manufacturing Operations?
Cut-off tools are vital machining instruments used to cut, trim, or separate workpieces across various industrial applications including automotive, aerospace, construction, metalworking, and electronics. These tools enable high-speed, clean, and precise cuts in materials such as metal, plastic, ceramic, or composites, making them indispensable for part fabrication, sheet metal work, and material sizing. Cut-off tools come in a variety of forms—ranging from abrasive wheels and rotary cutters to pneumatic and electric handheld models—each tailored to specific cutting needs and environments.

Their significance lies in their ability to provide straight, burr-free cuts with minimal material deformation, especially in mass production environments where speed and precision are crucial. As global manufacturing continues to move toward automation, lean production, and tighter tolerances, demand for high-performance cutting tools is rising. The market is also witnessing increased adoption across DIY, home improvement, and maintenance applications, thanks to the proliferation of compact and user-friendly variants designed for non-industrial users.

How Are Innovations in Material Science and Tool Design Enhancing Performance?
Technological advancements are significantly improving the durability, efficiency, and versatility of cut-off tools. High-performance cutting wheels made from aluminum oxide, silicon carbide, and diamond abrasives offer superior edge retention and heat resistance, supporting longer tool life and consistent cutting quality. Advanced coatings such as titanium nitride (TiN) and titanium aluminum nitride (TiAlN) on cutting inserts further enhance resistance to wear and thermal damage, making the tools suitable for high-speed or dry cutting environments.

Ergonomic design and safety enhancements are also evolving rapidly. Manufacturers are integrating vibration-dampening handles, adjustable guards, and quick-change discs into handheld tools to improve user comfort and minimize downtime. For automated systems, CNC-compatible cut-off tools with modularity, tool wear sensors, and coolant-through designs are enabling precision-controlled operations in complex manufacturing setups. Cordless electric variants powered by lithium-ion batteries are gaining popularity in portable applications, offering flexibility without compromising power.

Which End-Use Sectors and Applications Are Driving Demand for Cut-Off Tools?
The automotive industry remains one of the largest end-users of cut-off tools, leveraging them for cutting exhaust pipes, trimming body panels, and machining precision components. Aerospace manufacturers use them to slice through high-strength alloys and composites in structural parts production. Metal fabrication workshops rely on them for sheet cutting, bar trimming, and weld preparation, while construction professionals use them in rebar cutting, pipe sectioning, and demolition tasks.

In addition, the electronics and electrical sectors utilize micro cut-off tools in the assembly of circuit boards and connector fabrication. DIY and maintenance applications are also growing in relevance, especially with the rise in home improvement activities, where compact rotary tools are widely used for hobbyist projects and household repairs. Across industries, the need for speed, repeatability, and clean-edge finishing makes cut-off tools a core element in modern machining and assembly operations.

What Factors Are Fueling Market Growth for Cut-Off Tools Worldwide?
The growth in the cut-off tools market is driven by several operational, technological, and sector-specific factors. First, the increasing pace of industrial automation and CNC machining is expanding the use of precision cut-off tools in both high-volume and high-precision manufacturing. Second, the global uptrend in construction and infrastructure projects is boosting demand for durable and portable cutting solutions capable of operating in rugged environments.

Third, rapid advancements in material technology—both in tool construction and the substrates being cut—are creating demand for specialized tools that can handle exotic alloys, hardened metals, and layered composites. Fourth, the growth of small-scale manufacturing, DIY culture, and portable power tools is expanding the consumer segment of the market. Lastly, growing focus on workplace safety and operational efficiency is pushing manufacturers to innovate tools that are not only faster and more accurate but also ergonomic, low-vibration, and compliant with global safety standards. Collectively, these dynamics are shaping a robust, innovation-driven outlook for the global cut-off tools market.

SCOPE OF STUDY:

The report analyzes the Cut-Off Tools market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:
Technology (Electric Technology, Pneumatic Technology); Diameter (Below 3 inches Diameter, 3 - 6 inches Diameter, 6 - 9 inches Diameter); Type (Grip Cut-off Tool Type, Angle Cut-off Tool Type, Inline Cut-off Tool Type); End-Use (Automotive End-Use, Aerospace End-Use, Construction End-Use, Metal Fabrication End-Use, Woodworking End-Use, Electronics End-Use, Other End-Uses)

Geographic Regions/Countries:
World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 34 Featured) -
  • 3M
  • Bahco
  • Bosch
  • DeWalt
  • Flex-Elektrowerkzeuge
  • Hilti
  • Ingersoll Cutting Tool
  • Makita
  • Metabo
  • Milwaukee Tool
  • Peak Toolworks
  • Ridgid
  • Sandvik AB
  • Snap-on
  • Sumitomo Electric
  • TaeguTec Ltd.
  • Total Tools
  • Walter AG
  • Wilmar Corporation
  • YG-1 Co., Ltd.
AI INTEGRATIONS
We`re transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR
Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

Please note: Reports are sold as single-site single-user licenses. Electronic versions require 24-48 hours as each copy is customized to the client with digital controls and custom watermarks. The Publisher uses digital controls protecting against copying and printing is restricted to one full copy to be used at the same location.

The latest version of Adobe Acrobat Reader is required to view the report. Upon ordering an electronic version, the Publisher will provide a link to download the purchased report.

Prior to fulfillment of an order, the client will be required to sign a document detailing the purchase terms for a publication from this publisher.

Table of Contents

473 Pages
I. METHODOLOGY
II. EXECUTIVE SUMMARY
1. MARKET OVERVIEW
Influencer Market Insights
World Market Trajectories
Tariff Impact on Global Supply Chain Patterns
Cutaneous and Systemic Leishmaniasis – Global Key Competitors Percentage Market Share in 2025 (E)
Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
2. FOCUS ON SELECT PLAYERS
3. MARKET TRENDS & DRIVERS
Rising Prevalence in Endemic Regions Propels Global Demand for Leishmaniasis Diagnostics and Therapeutics
Expansion of Public Health Surveillance Initiatives Strengthens Case for Early Detection Solutions
Growing Investments in Tropical Disease Research Throws the Spotlight on Leishmaniasis Drug Development
Limited Treatment Access in Developing Regions Spurs Need for Affordable Therapeutic Options
Global Health NGO and Government Partnerships Accelerate Mass Screening and Awareness Campaigns
Emerging Drug Resistance Patterns in Leishmania Parasites Drive Innovation in Antileishmanial Compounds
Increased Adoption of Liposomal Amphotericin B Sustains Market for Targeted Systemic Therapies
Climate Change and Human Migration Expand Leishmaniasis Transmission Zones Globally
Demand for Point-of-Care Diagnostics Strengthens Market for Field-Deployable Detection Kits
Focus on Animal Reservoir Control Boosts Demand for Vector Control and Zoonotic Prevention Tools
R&D Advances in Vaccine Development Create Long-Term Market Opportunities
4. GLOBAL MARKET PERSPECTIVE
TABLE 1: World Cutaneous and Systemic Leishmaniasis Market Analysis of Annual Sales in US$ Thousand for Years 2014 through 2030
TABLE 2: World Recent Past, Current & Future Analysis for Cutaneous and Systemic Leishmaniasis by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
TABLE 3: World Historic Review for Cutaneous and Systemic Leishmaniasis by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
TABLE 4: World 16-Year Perspective for Cutaneous and Systemic Leishmaniasis by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2014, 2025 & 2030
TABLE 5: World Recent Past, Current & Future Analysis for Pentavalent Antimonials Drug Class by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
TABLE 6: World Historic Review for Pentavalent Antimonials Drug Class by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
TABLE 7: World 16-Year Perspective for Pentavalent Antimonials Drug Class by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
TABLE 8: World Recent Past, Current & Future Analysis for Antifungals Drug Class by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
TABLE 9: World Historic Review for Antifungals Drug Class by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
TABLE 10: World 16-Year Perspective for Antifungals Drug Class by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
TABLE 11: World Recent Past, Current & Future Analysis for Anti-Lesihmanial / Antimicrobials Drug Class by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
TABLE 12: World Historic Review for Anti-Lesihmanial / Antimicrobials Drug Class by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
TABLE 13: World 16-Year Perspective for Anti-Lesihmanial / Antimicrobials Drug Class by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
TABLE 14: World Recent Past, Current & Future Analysis for Hospital Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
TABLE 15: World Historic Review for Hospital Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
TABLE 16: World 16-Year Perspective for Hospital Pharmacies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
TABLE 17: World Recent Past, Current & Future Analysis for Retail Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
TABLE 18: World Historic Review for Retail Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
TABLE 19: World 16-Year Perspective for Retail Pharmacies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
TABLE 20: World Recent Past, Current & Future Analysis for Drug Stores by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
TABLE 21: World Historic Review for Drug Stores by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
TABLE 22: World 16-Year Perspective for Drug Stores by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
TABLE 23: World Recent Past, Current & Future Analysis for Online Distribution Channel by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
TABLE 24: World Historic Review for Online Distribution Channel by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
TABLE 25: World 16-Year Perspective for Online Distribution Channel by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
TABLE 26: World Recent Past, Current & Future Analysis for Oral Route by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
TABLE 27: World Historic Review for Oral Route by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
TABLE 28: World 16-Year Perspective for Oral Route by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
TABLE 29: World Recent Past, Current & Future Analysis for Injectable Route by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
TABLE 30: World Historic Review for Injectable Route by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
TABLE 31: World 16-Year Perspective for Injectable Route by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
TABLE 32: World Recent Past, Current & Future Analysis for Topical Route by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
TABLE 33: World Historic Review for Topical Route by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
TABLE 34: World 16-Year Perspective for Topical Route by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
TABLE 35: World Recent Past, Current & Future Analysis for Cutaneous Leishmaniasis Indication by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
TABLE 36: World Historic Review for Cutaneous Leishmaniasis Indication by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
TABLE 37: World 16-Year Perspective for Cutaneous Leishmaniasis Indication by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
TABLE 38: World Recent Past, Current & Future Analysis for Mucosal Leishmaniasis Indication by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
TABLE 39: World Historic Review for Mucosal Leishmaniasis Indication by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
TABLE 40: World 16-Year Perspective for Mucosal Leishmaniasis Indication by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
TABLE 41: World Recent Past, Current & Future Analysis for Visceral Leishmaniasis Indication by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
TABLE 42: World Historic Review for Visceral Leishmaniasis Indication by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
TABLE 43: World 16-Year Perspective for Visceral Leishmaniasis Indication by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
III. MARKET ANALYSIS
UNITED STATES
Cutaneous and Systemic Leishmaniasis Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
TABLE 44: USA Recent Past, Current & Future Analysis for Cutaneous and Systemic Leishmaniasis by Drug Class - Pentavalent Antimonials Drug Class, Antifungals Drug Class and Anti-Lesihmanial / Antimicrobials Drug Class - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 45: USA Historic Review for Cutaneous and Systemic Leishmaniasis by Drug Class - Pentavalent Antimonials Drug Class, Antifungals Drug Class and Anti-Lesihmanial / Antimicrobials Drug Class Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
TABLE 46: USA 16-Year Perspective for Cutaneous and Systemic Leishmaniasis by Drug Class - Percentage Breakdown of Value Sales for Pentavalent Antimonials Drug Class, Antifungals Drug Class and Anti-Lesihmanial / Antimicrobials Drug Class for the Years 2014, 2025 & 2030
TABLE 47: USA Recent Past, Current & Future Analysis for Cutaneous and Systemic Leishmaniasis by Distribution Channel - Hospital Pharmacies, Retail Pharmacies, Drug Stores and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 48: USA Historic Review for Cutaneous and Systemic Leishmaniasis by Distribution Channel - Hospital Pharmacies, Retail Pharmacies, Drug Stores and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
TABLE 49: USA 16-Year Perspective for Cutaneous and Systemic Leishmaniasis by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies, Drug Stores and Online Distribution Channel for the Years 2014, 2025 & 2030
TABLE 50: USA Recent Past, Current & Future Analysis for Cutaneous and Systemic Leishmaniasis by Administration Route - Oral Route, Injectable Route and Topical Route - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 51: USA Historic Review for Cutaneous and Systemic Leishmaniasis by Administration Route - Oral Route, Injectable Route and Topical Route Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
TABLE 52: USA 16-Year Perspective for Cutaneous and Systemic Leishmaniasis by Administration Route - Percentage Breakdown of Value Sales for Oral Route, Injectable Route and Topical Route for the Years 2014, 2025 & 2030
TABLE 53: USA Recent Past, Current & Future Analysis for Cutaneous and Systemic Leishmaniasis by Indication - Cutaneous Leishmaniasis Indication, Mucosal Leishmaniasis Indication and Visceral Leishmaniasis Indication - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 54: USA Historic Review for Cutaneous and Systemic Leishmaniasis by Indication - Cutaneous Leishmaniasis Indication, Mucosal Leishmaniasis Indication and Visceral Leishmaniasis Indication Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
TABLE 55: USA 16-Year Perspective for Cutaneous and Systemic Leishmaniasis by Indication - Percentage Breakdown of Value Sales for Cutaneous Leishmaniasis Indication, Mucosal Leishmaniasis Indication and Visceral Leishmaniasis Indication for the Years 2014, 2025 & 2030
CANADA
TABLE 56: Canada Recent Past, Current & Future Analysis for Cutaneous and Systemic Leishmaniasis by Drug Class - Pentavalent Antimonials Drug Class, Antifungals Drug Class and Anti-Lesihmanial / Antimicrobials Drug Class - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 57: Canada Historic Review for Cutaneous and Systemic Leishmaniasis by Drug Class - Pentavalent Antimonials Drug Class, Antifungals Drug Class and Anti-Lesihmanial / Antimicrobials Drug Class Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
TABLE 58: Canada 16-Year Perspective for Cutaneous and Systemic Leishmaniasis by Drug Class - Percentage Breakdown of Value Sales for Pentavalent Antimonials Drug Class, Antifungals Drug Class and Anti-Lesihmanial / Antimicrobials Drug Class for the Years 2014, 2025 & 2030
TABLE 59: Canada Recent Past, Current & Future Analysis for Cutaneous and Systemic Leishmaniasis by Distribution Channel - Hospital Pharmacies, Retail Pharmacies, Drug Stores and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 60: Canada Historic Review for Cutaneous and Systemic Leishmaniasis by Distribution Channel - Hospital Pharmacies, Retail Pharmacies, Drug Stores and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
TABLE 61: Canada 16-Year Perspective for Cutaneous and Systemic Leishmaniasis by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies, Drug Stores and Online Distribution Channel for the Years 2014, 2025 & 2030
TABLE 62: Canada Recent Past, Current & Future Analysis for Cutaneous and Systemic Leishmaniasis by Administration Route - Oral Route, Injectable Route and Topical Route - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 63: Canada Historic Review for Cutaneous and Systemic Leishmaniasis by Administration Route - Oral Route, Injectable Route and Topical Route Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
TABLE 64: Canada 16-Year Perspective for Cutaneous and Systemic Leishmaniasis by Administration Route - Percentage Breakdown of Value Sales for Oral Route, Injectable Route and Topical Route for the Years 2014, 2025 & 2030
TABLE 65: Canada Recent Past, Current & Future Analysis for Cutaneous and Systemic Leishmaniasis by Indication - Cutaneous Leishmaniasis Indication, Mucosal Leishmaniasis Indication and Visceral Leishmaniasis Indication - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 66: Canada Historic Review for Cutaneous and Systemic Leishmaniasis by Indication - Cutaneous Leishmaniasis Indication, Mucosal Leishmaniasis Indication and Visceral Leishmaniasis Indication Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
TABLE 67: Canada 16-Year Perspective for Cutaneous and Systemic Leishmaniasis by Indication - Percentage Breakdown of Value Sales for Cutaneous Leishmaniasis Indication, Mucosal Leishmaniasis Indication and Visceral Leishmaniasis Indication for the Years 2014, 2025 & 2030
JAPAN
Cutaneous and Systemic Leishmaniasis Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
TABLE 68: Japan Recent Past, Current & Future Analysis for Cutaneous and Systemic Leishmaniasis by Drug Class - Pentavalent Antimonials Drug Class, Antifungals Drug Class and Anti-Lesihmanial / Antimicrobials Drug Class - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 69: Japan Historic Review for Cutaneous and Systemic Leishmaniasis by Drug Class - Pentavalent Antimonials Drug Class, Antifungals Drug Class and Anti-Lesihmanial / Antimicrobials Drug Class Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
TABLE 70: Japan 16-Year Perspective for Cutaneous and Systemic Leishmaniasis by Drug Class - Percentage Breakdown of Value Sales for Pentavalent Antimonials Drug Class, Antifungals Drug Class and Anti-Lesihmanial / Antimicrobials Drug Class for the Years 2014, 2025 & 2030
TABLE 71: Japan Recent Past, Current & Future Analysis for Cutaneous and Systemic Leishmaniasis by Distribution Channel - Hospital Pharmacies, Retail Pharmacies, Drug Stores and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 72: Japan Historic Review for Cutaneous and Systemic Leishmaniasis by Distribution Channel - Hospital Pharmacies, Retail Pharmacies, Drug Stores and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
TABLE 73: Japan 16-Year Perspective for Cutaneous and Systemic Leishmaniasis by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies, Drug Stores and Online Distribution Channel for the Years 2014, 2025 & 2030
TABLE 74: Japan Recent Past, Current & Future Analysis for Cutaneous and Systemic Leishmaniasis by Administration Route - Oral Route, Injectable Route and Topical Route - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 75: Japan Historic Review for Cutaneous and Systemic Leishmaniasis by Administration Route - Oral Route, Injectable Route and Topical Route Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
TABLE 76: Japan 16-Year Perspective for Cutaneous and Systemic Leishmaniasis by Administration Route - Percentage Breakdown of Value Sales for Oral Route, Injectable Route and Topical Route for the Years 2014, 2025 & 2030
TABLE 77: Japan Recent Past, Current & Future Analysis for Cutaneous and Systemic Leishmaniasis by Indication - Cutaneous Leishmaniasis Indication, Mucosal Leishmaniasis Indication and Visceral Leishmaniasis Indication - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 78: Japan Historic Review for Cutaneous and Systemic Leishmaniasis by Indication - Cutaneous Leishmaniasis Indication, Mucosal Leishmaniasis Indication and Visceral Leishmaniasis Indication Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
TABLE 79: Japan 16-Year Perspective for Cutaneous and Systemic Leishmaniasis by Indication - Percentage Breakdown of Value Sales for Cutaneous Leishmaniasis Indication, Mucosal Leishmaniasis Indication and Visceral Leishmaniasis Indication for the Years 2014, 2025 & 2030
CHINA
Cutaneous and Systemic Leishmaniasis Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
TABLE 80: China Recent Past, Current & Future Analysis for Cutaneous and Systemic Leishmaniasis by Drug Class - Pentavalent Antimonials Drug Class, Antifungals Drug Class and Anti-Lesihmanial / Antimicrobials Drug Class - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 81: China Historic Review for Cutaneous and Systemic Leishmaniasis by Drug Class - Pentavalent Antimonials Drug Class, Antifungals Drug Class and Anti-Lesihmanial / Antimicrobials Drug Class Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
TABLE 82: China 16-Year Perspective for Cutaneous and Systemic Leishmaniasis by Drug Class - Percentage Breakdown of Value Sales for Pentavalent Antimonials Drug Class, Antifungals Drug Class and Anti-Lesihmanial / Antimicrobials Drug Class for the Years 2014, 2025 & 2030
TABLE 83: China Recent Past, Current & Future Analysis for Cutaneous and Systemic Leishmaniasis by Distribution Channel - Hospital Pharmacies, Retail Pharmacies, Drug Stores and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 84: China Historic Review for Cutaneous and Systemic Leishmaniasis by Distribution Channel - Hospital Pharmacies, Retail Pharmacies, Drug Stores and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
TABLE 85: China 16-Year Perspective for Cutaneous and Systemic Leishmaniasis by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies, Drug Stores and Online Distribution Channel for the Years 2014, 2025 & 2030
TABLE 86: China Recent Past, Current & Future Analysis for Cutaneous and Systemic Leishmaniasis by Administration Route - Oral Route, Injectable Route and Topical Route - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 87: China Historic Review for Cutaneous and Systemic Leishmaniasis by Administration Route - Oral Route, Injectable Route and Topical Route Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
TABLE 88: China 16-Year Perspective for Cutaneous and Systemic Leishmaniasis by Administration Route - Percentage Breakdown of Value Sales for Oral Route, Injectable Route and Topical Route for the Years 2014, 2025 & 2030
TABLE 89: China Recent Past, Current & Future Analysis for Cutaneous and Systemic Leishmaniasis by Indication - Cutaneous Leishmaniasis Indication, Mucosal Leishmaniasis Indication and Visceral Leishmaniasis Indication - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 90: China Historic Review for Cutaneous and Systemic Leishmaniasis by Indication - Cutaneous Leishmaniasis Indication, Mucosal Leishmaniasis Indication and Visceral Leishmaniasis Indication Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
TABLE 91: China 16-Year Perspective for Cutaneous and Systemic Leishmaniasis by Indication - Percentage Breakdown of Value Sales for Cutaneous Leishmaniasis Indication, Mucosal Leishmaniasis Indication and Visceral Leishmaniasis Indication for the Years 2014, 2025 & 2030
EUROPE
Cutaneous and Systemic Leishmaniasis Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
TABLE 92: Europe Recent Past, Current & Future Analysis for Cutaneous and Systemic Leishmaniasis by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
TABLE 93: Europe Historic Review for Cutaneous and Systemic Leishmaniasis by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
TABLE 94: Europe 16-Year Perspective for Cutaneous and Systemic Leishmaniasis by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2014, 2025 & 2030
TABLE 95: Europe Recent Past, Current & Future Analysis for Cutaneous and Systemic Leishmaniasis by Drug Class - Pentavalent Antimonials Drug Class, Antifungals Drug Class and Anti-Lesihmanial / Antimicrobials Drug Class - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 96: Europe Historic Review for Cutaneous and Systemic Leishmaniasis by Drug Class - Pentavalent Antimonials Drug Class, Antifungals Drug Class and Anti-Lesihmanial / Antimicrobials Drug Class Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
TABLE 97: Europe 16-Year Perspective for Cutaneous and Systemic Leishmaniasis by Drug Class - Percentage Breakdown of Value Sales for Pentavalent Antimonials Drug Class, Antifungals Drug Class and Anti-Lesihmanial / Antimicrobials Drug Class for the Years 2014, 2025 & 2030
TABLE 98: Europe Recent Past, Current & Future Analysis for Cutaneous and Systemic Leishmaniasis by Distribution Channel - Hospital Pharmacies, Retail Pharmacies, Drug Stores and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 99: Europe Historic Review for Cutaneous and Systemic Leishmaniasis by Distribution Channel - Hospital Pharmacies, Retail Pharmacies, Drug Stores and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
TABLE 100: Europe 16-Year Perspective for Cutaneous and Systemic Leishmaniasis by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies, Drug Stores and Online Distribution Channel for the Years 2014, 2025 & 2030
TABLE 101: Europe Recent Past, Current & Future Analysis for Cutaneous and Systemic Leishmaniasis by Administration Route - Oral Route, Injectable Route and Topical Route - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 102: Europe Historic Review for Cutaneous and Systemic Leishmaniasis by Administration Route - Oral Route, Injectable Route and Topical Route Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
TABLE 103: Europe 16-Year Perspective for Cutaneous and Systemic Leishmaniasis by Administration Route - Percentage Breakdown of Value Sales for Oral Route, Injectable Route and Topical Route for the Years 2014, 2025 & 2030
TABLE 104: Europe Recent Past, Current & Future Analysis for Cutaneous and Systemic Leishmaniasis by Indication - Cutaneous Leishmaniasis Indication, Mucosal Leishmaniasis Indication and Visceral Leishmaniasis Indication - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 105: Europe Historic Review for Cutaneous and Systemic Leishmaniasis by Indication - Cutaneous Leishmaniasis Indication, Mucosal Leishmaniasis Indication and Visceral Leishmaniasis Indication Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
TABLE 106: Europe 16-Year Perspective for Cutaneous and Systemic Leishmaniasis by Indication - Percentage Breakdown of Value Sales for Cutaneous Leishmaniasis Indication, Mucosal Leishmaniasis Indication and Visceral Leishmaniasis Indication for the Years 2014, 2025 & 2030
FRANCE
Cutaneous and Systemic Leishmaniasis Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
TABLE 107: France Recent Past, Current & Future Analysis for Cutaneous and Systemic Leishmaniasis by Drug Class - Pentavalent Antimonials Drug Class, Antifungals Drug Class and Anti-Lesihmanial / Antimicrobials Drug Class - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 108: France Historic Review for Cutaneous and Systemic Leishmaniasis by Drug Class - Pentavalent Antimonials Drug Class, Antifungals Drug Class and Anti-Lesihmanial / Antimicrobials Drug Class Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
TABLE 109: France 16-Year Perspective for Cutaneous and Systemic Leishmaniasis by Drug Class - Percentage Breakdown of Value Sales for Pentavalent Antimonials Drug Class, Antifungals Drug Class and Anti-Lesihmanial / Antimicrobials Drug Class for the Years 2014, 2025 & 2030
TABLE 110: France Recent Past, Current & Future Analysis for Cutaneous and Systemic Leishmaniasis by Distribution Channel - Hospital Pharmacies, Retail Pharmacies, Drug Stores and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 111: France Historic Review for Cutaneous and Systemic Leishmaniasis by Distribution Channel - Hospital Pharmacies, Retail Pharmacies, Drug Stores and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
TABLE 112: France 16-Year Perspective for Cutaneous and Systemic Leishmaniasis by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies, Drug Stores and Online Distribution Channel for the Years 2014, 2025 & 2030
TABLE 113: France Recent Past, Current & Future Analysis for Cutaneous and Systemic Leishmaniasis by Administration Route - Oral Route, Injectable Route and Topical Route - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 114: France Historic Review for Cutaneous and Systemic Leishmaniasis by Administration Route - Oral Route, Injectable Route and Topical Route Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
TABLE 115: France 16-Year Perspective for Cutaneous and Systemic Leishmaniasis by Administration Route - Percentage Breakdown of Value Sales for Oral Route, Injectable Route and Topical Route for the Years 2014, 2025 & 2030
TABLE 116: France Recent Past, Current & Future Analysis for Cutaneous and Systemic Leishmaniasis by Indication - Cutaneous Leishmaniasis Indication, Mucosal Leishmaniasis Indication and Visceral Leishmaniasis Indication - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 117: France Historic Review for Cutaneous and Systemic Leishmaniasis by Indication - Cutaneous Leishmaniasis Indication, Mucosal Leishmaniasis Indication and Visceral Leishmaniasis Indication Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
TABLE 118: France 16-Year Perspective for Cutaneous and Systemic Leishmaniasis by Indication - Percentage Breakdown of Value Sales for Cutaneous Leishmaniasis Indication, Mucosal Leishmaniasis Indication and Visceral Leishmaniasis Indication for the Years 2014, 2025 & 2030
GERMANY
Cutaneous and Systemic Leishmaniasis Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
TABLE 119: Germany Recent Past, Current & Future Analysis for Cutaneous and Systemic Leishmaniasis by Drug Class - Pentavalent Antimonials Drug Class, Antifungals Drug Class and Anti-Lesihmanial / Antimicrobials Drug Class - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 120: Germany Historic Review for Cutaneous and Systemic Leishmaniasis by Drug Class - Pentavalent Antimonials Drug Class, Antifungals Drug Class and Anti-Lesihmanial / Antimicrobials Drug Class Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
TABLE 121: Germany 16-Year Perspective for Cutaneous and Systemic Leishmaniasis by Drug Class - Percentage Breakdown of Value Sales for Pentavalent Antimonials Drug Class, Antifungals Drug Class and Anti-Lesihmanial / Antimicrobials Drug Class for the Years 2014, 2025 & 2030
TABLE 122: Germany Recent Past, Current & Future Analysis for Cutaneous and Systemic Leishmaniasis by Distribution Channel - Hospital Pharmacies, Retail Pharmacies, Drug Stores and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 123: Germany Historic Review for Cutaneous and Systemic Leishmaniasis by Distribution Channel - Hospital Pharmacies, Retail Pharmacies, Drug Stores and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
TABLE 124: Germany 16-Year Perspective for Cutaneous and Systemic Leishmaniasis by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies, Drug Stores and Online Distribution Channel for the Years 2014, 2025 & 2030
TABLE 125: Germany Recent Past, Current & Future Analysis for Cutaneous and Systemic Leishmaniasis by Administration Route - Oral Route, Injectable Route and Topical Route - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 126: Germany Historic Review for Cutaneous and Systemic Leishmaniasis by Administration Route - Oral Route, Injectable Route and Topical Route Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
TABLE 127: Germany 16-Year Perspective for Cutaneous and Systemic Leishmaniasis by Administration Route - Percentage Breakdown of Value Sales for Oral Route, Injectable Route and Topical Route for the Years 2014, 2025 & 2030
TABLE 128: Germany Recent Past, Current & Future Analysis for Cutaneous and Systemic Leishmaniasis by Indication - Cutaneous Leishmaniasis Indication, Mucosal Leishmaniasis Indication and Visceral Leishmaniasis Indication - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 129: Germany Historic Review for Cutaneous and Systemic Leishmaniasis by Indication - Cutaneous Leishmaniasis Indication, Mucosal Leishmaniasis Indication and Visceral Leishmaniasis Indication Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
TABLE 130: Germany 16-Year Perspective for Cutaneous and Systemic Leishmaniasis by Indication - Percentage Breakdown of Value Sales for Cutaneous Leishmaniasis Indication, Mucosal Leishmaniasis Indication and Visceral Leishmaniasis Indication for the Years 2014, 2025 & 2030
ITALY
TABLE 131: Italy Recent Past, Current & Future Analysis for Cutaneous and Systemic Leishmaniasis by Drug Class - Pentavalent Antimonials Drug Class, Antifungals Drug Class and Anti-Lesihmanial / Antimicrobials Drug Class - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 132: Italy Historic Review for Cutaneous and Systemic Leishmaniasis by Drug Class - Pentavalent Antimonials Drug Class, Antifungals Drug Class and Anti-Lesihmanial / Antimicrobials Drug Class Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
TABLE 133: Italy 16-Year Perspective for Cutaneous and Systemic Leishmaniasis by Drug Class - Percentage Breakdown of Value Sales for Pentavalent Antimonials Drug Class, Antifungals Drug Class and Anti-Lesihmanial / Antimicrobials Drug Class for the Years 2014, 2025 & 2030
TABLE 134: Italy Recent Past, Current & Future Analysis for Cutaneous and Systemic Leishmaniasis by Distribution Channel - Hospital Pharmacies, Retail Pharmacies, Drug Stores and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 135: Italy Historic Review for Cutaneous and Systemic Leishmaniasis by Distribution Channel - Hospital Pharmacies, Retail Pharmacies, Drug Stores and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
TABLE 136: Italy 16-Year Perspective for Cutaneous and Systemic Leishmaniasis by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies, Drug Stores and Online Distribution Channel for the Years 2014, 2025 & 2030
TABLE 137: Italy Recent Past, Current & Future Analysis for Cutaneous and Systemic Leishmaniasis by Administration Route - Oral Route, Injectable Route and Topical Route - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 138: Italy Historic Review for Cutaneous and Systemic Leishmaniasis by Administration Route - Oral Route, Injectable Route and Topical Route Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
TABLE 139: Italy 16-Year Perspective for Cutaneous and Systemic Leishmaniasis by Administration Route - Percentage Breakdown of Value Sales for Oral Route, Injectable Route and Topical Route for the Years 2014, 2025 & 2030
TABLE 140: Italy Recent Past, Current & Future Analysis for Cutaneous and Systemic Leishmaniasis by Indication - Cutaneous Leishmaniasis Indication, Mucosal Leishmaniasis Indication and Visceral Leishmaniasis Indication - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 141: Italy Historic Review for Cutaneous and Systemic Leishmaniasis by Indication - Cutaneous Leishmaniasis Indication, Mucosal Leishmaniasis Indication and Visceral Leishmaniasis Indication Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
TABLE 142: Italy 16-Year Perspective for Cutaneous and Systemic Leishmaniasis by Indication - Percentage Breakdown of Value Sales for Cutaneous Leishmaniasis Indication, Mucosal Leishmaniasis Indication and Visceral Leishmaniasis Indication for the Years 2014, 2025 & 2030
UNITED KINGDOM
Cutaneous and Systemic Leishmaniasis Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
TABLE 143: UK Recent Past, Current & Future Analysis for Cutaneous and Systemic Leishmaniasis by Drug Class - Pentavalent Antimonials Drug Class, Antifungals Drug Class and Anti-Lesihmanial / Antimicrobials Drug Class - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 144: UK Historic Review for Cutaneous and Systemic Leishmaniasis by Drug Class - Pentavalent Antimonials Drug Class, Antifungals Drug Class and Anti-Lesihmanial / Antimicrobials Drug Class Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
TABLE 145: UK 16-Year Perspective for Cutaneous and Systemic Leishmaniasis by Drug Class - Percentage Breakdown of Value Sales for Pentavalent Antimonials Drug Class, Antifungals Drug Class and Anti-Lesihmanial / Antimicrobials Drug Class for the Years 2014, 2025 & 2030
TABLE 146: UK Recent Past, Current & Future Analysis for Cutaneous and Systemic Leishmaniasis by Distribution Channel - Hospital Pharmacies, Retail Pharmacies, Drug Stores and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 147: UK Historic Review for Cutaneous and Systemic Leishmaniasis by Distribution Channel - Hospital Pharmacies, Retail Pharmacies, Drug Stores and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
TABLE 148: UK 16-Year Perspective for Cutaneous and Systemic Leishmaniasis by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies, Drug Stores and Online Distribution Channel for the Years 2014, 2025 & 2030
TABLE 149: UK Recent Past, Current & Future Analysis for Cutaneous and Systemic Leishmaniasis by Administration Route - Oral Route, Injectable Route and Topical Route - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 150: UK Historic Review for Cutaneous and Systemic Leishmaniasis by Administration Route - Oral Route, Injectable Route and Topical Route Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
TABLE 151: UK 16-Year Perspective for Cutaneous and Systemic Leishmaniasis by Administration Route - Percentage Breakdown of Value Sales for Oral Route, Injectable Route and Topical Route for the Years 2014, 2025 & 2030
TABLE 152: UK Recent Past, Current & Future Analysis for Cutaneous and Systemic Leishmaniasis by Indication - Cutaneous Leishmaniasis Indication, Mucosal Leishmaniasis Indication and Visceral Leishmaniasis Indication - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 153: UK Historic Review for Cutaneous and Systemic Leishmaniasis by Indication - Cutaneous Leishmaniasis Indication, Mucosal Leishmaniasis Indication and Visceral Leishmaniasis Indication Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
TABLE 154: UK 16-Year Perspective for Cutaneous and Systemic Leishmaniasis by Indication - Percentage Breakdown of Value Sales for Cutaneous Leishmaniasis Indication, Mucosal Leishmaniasis Indication and Visceral Leishmaniasis Indication for the Years 2014, 2025 & 2030
SPAIN
TABLE 155: Spain Recent Past, Current & Future Analysis for Cutaneous and Systemic Leishmaniasis by Drug Class - Pentavalent Antimonials Drug Class, Antifungals Drug Class and Anti-Lesihmanial / Antimicrobials Drug Class - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 156: Spain Historic Review for Cutaneous and Systemic Leishmaniasis by Drug Class - Pentavalent Antimonials Drug Class, Antifungals Drug Class and Anti-Lesihmanial / Antimicrobials Drug Class Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
TABLE 157: Spain 16-Year Perspective for Cutaneous and Systemic Leishmaniasis by Drug Class - Percentage Breakdown of Value Sales for Pentavalent Antimonials Drug Class, Antifungals Drug Class and Anti-Lesihmanial / Antimicrobials Drug Class for the Years 2014, 2025 & 2030
TABLE 158: Spain Recent Past, Current & Future Analysis for Cutaneous and Systemic Leishmaniasis by Distribution Channel - Hospital Pharmacies, Retail Pharmacies, Drug Stores and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 159: Spain Historic Review for Cutaneous and Systemic Leishmaniasis by Distribution Channel - Hospital Pharmacies, Retail Pharmacies, Drug Stores and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
TABLE 160: Spain 16-Year Perspective for Cutaneous and Systemic Leishmaniasis by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies, Drug Stores and Online Distribution Channel for the Years 2014, 2025 & 2030
TABLE 161: Spain Recent Past, Current & Future Analysis for Cutaneous and Systemic Leishmaniasis by Administration Route - Oral Route, Injectable Route and Topical Route - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 162: Spain Historic Review for Cutaneous and Systemic Leishmaniasis by Administration Route - Oral Route, Injectable Route and Topical Route Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
TABLE 163: Spain 16-Year Perspective for Cutaneous and Systemic Leishmaniasis by Administration Route - Percentage Breakdown of Value Sales for Oral Route, Injectable Route and Topical Route for the Years 2014, 2025 & 2030
TABLE 164: Spain Recent Past, Current & Future Analysis for Cutaneous and Systemic Leishmaniasis by Indication - Cutaneous Leishmaniasis Indication, Mucosal Leishmaniasis Indication and Visceral Leishmaniasis Indication - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 165: Spain Historic Review for Cutaneous and Systemic Leishmaniasis by Indication - Cutaneous Leishmaniasis Indication, Mucosal Leishmaniasis Indication and Visceral Leishmaniasis Indication Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
TABLE 166: Spain 16-Year Perspective for Cutaneous and Systemic Leishmaniasis by Indication - Percentage Breakdown of Value Sales for Cutaneous Leishmaniasis Indication, Mucosal Leishmaniasis Indication and Visceral Leishmaniasis Indication for the Years 2014, 2025 & 2030
RUSSIA
TABLE 167: Russia Recent Past, Current & Future Analysis for Cutaneous and Systemic Leishmaniasis by Drug Class - Pentavalent Antimonials Drug Class, Antifungals Drug Class and Anti-Lesihmanial / Antimicrobials Drug Class - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 168: Russia Historic Review for Cutaneous and Systemic Leishmaniasis by Drug Class - Pentavalent Antimonials Drug Class, Antifungals Drug Class and Anti-Lesihmanial / Antimicrobials Drug Class Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
TABLE 169: Russia 16-Year Perspective for Cutaneous and Systemic Leishmaniasis by Drug Class - Percentage Breakdown of Value Sales for Pentavalent Antimonials Drug Class, Antifungals Drug Class and Anti-Lesihmanial / Antimicrobials Drug Class for the Years 2014, 2025 & 2030
TABLE 170: Russia Recent Past, Current & Future Analysis for Cutaneous and Systemic Leishmaniasis by Distribution Channel - Hospital Pharmacies, Retail Pharmacies, Drug Stores and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 171: Russia Historic Review for Cutaneous and Systemic Leishmaniasis by Distribution Channel - Hospital Pharmacies, Retail Pharmacies, Drug Stores and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
TABLE 172: Russia 16-Year Perspective for Cutaneous and Systemic Leishmaniasis by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies, Drug Stores and Online Distribution Channel for the Years 2014, 2025 & 2030
TABLE 173: Russia Recent Past, Current & Future Analysis for Cutaneous and Systemic Leishmaniasis by Administration Route - Oral Route, Injectable Route and Topical Route - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 174: Russia Historic Review for Cutaneous and Systemic Leishmaniasis by Administration Route - Oral Route, Injectable Route and Topical Route Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
TABLE 175: Russia 16-Year Perspective for Cutaneous and Systemic Leishmaniasis by Administration Route - Percentage Breakdown of Value Sales for Oral Route, Injectable Route and Topical Route for the Years 2014, 2025 & 2030
TABLE 176: Russia Recent Past, Current & Future Analysis for Cutaneous and Systemic Leishmaniasis by Indication - Cutaneous Leishmaniasis Indication, Mucosal Leishmaniasis Indication and Visceral Leishmaniasis Indication - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 177: Russia Historic Review for Cutaneous and Systemic Leishmaniasis by Indication - Cutaneous Leishmaniasis Indication, Mucosal Leishmaniasis Indication and Visceral Leishmaniasis Indication Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
TABLE 178: Russia 16-Year Perspective for Cutaneous and Systemic Leishmaniasis by Indication - Percentage Breakdown of Value Sales for Cutaneous Leishmaniasis Indication, Mucosal Leishmaniasis Indication and Visceral Leishmaniasis Indication for the Years 2014, 2025 & 2030
REST OF EUROPE
TABLE 179: Rest of Europe Recent Past, Current & Future Analysis for Cutaneous and Systemic Leishmaniasis by Drug Class - Pentavalent Antimonials Drug Class, Antifungals Drug Class and Anti-Lesihmanial / Antimicrobials Drug Class - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 180: Rest of Europe Historic Review for Cutaneous and Systemic Leishmaniasis by Drug Class - Pentavalent Antimonials Drug Class, Antifungals Drug Class and Anti-Lesihmanial / Antimicrobials Drug Class Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
TABLE 181: Rest of Europe 16-Year Perspective for Cutaneous and Systemic Leishmaniasis by Drug Class - Percentage Breakdown of Value Sales for Pentavalent Antimonials Drug Class, Antifungals Drug Class and Anti-Lesihmanial / Antimicrobials Drug Class for the Years 2014, 2025 & 2030
TABLE 182: Rest of Europe Recent Past, Current & Future Analysis for Cutaneous and Systemic Leishmaniasis by Distribution Channel - Hospital Pharmacies, Retail Pharmacies, Drug Stores and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 183: Rest of Europe Historic Review for Cutaneous and Systemic Leishmaniasis by Distribution Channel - Hospital Pharmacies, Retail Pharmacies, Drug Stores and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
TABLE 184: Rest of Europe 16-Year Perspective for Cutaneous and Systemic Leishmaniasis by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies, Drug Stores and Online Distribution Channel for the Years 2014, 2025 & 2030
TABLE 185: Rest of Europe Recent Past, Current & Future Analysis for Cutaneous and Systemic Leishmaniasis by Administration Route - Oral Route, Injectable Route and Topical Route - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 186: Rest of Europe Historic Review for Cutaneous and Systemic Leishmaniasis by Administration Route - Oral Route, Injectable Route and Topical Route Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
TABLE 187: Rest of Europe 16-Year Perspective for Cutaneous and Systemic Leishmaniasis by Administration Route - Percentage Breakdown of Value Sales for Oral Route, Injectable Route and Topical Route for the Years 2014, 2025 & 2030
TABLE 188: Rest of Europe Recent Past, Current & Future Analysis for Cutaneous and Systemic Leishmaniasis by Indication - Cutaneous Leishmaniasis Indication, Mucosal Leishmaniasis Indication and Visceral Leishmaniasis Indication - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 189: Rest of Europe Historic Review for Cutaneous and Systemic Leishmaniasis by Indication - Cutaneous Leishmaniasis Indication, Mucosal Leishmaniasis Indication and Visceral Leishmaniasis Indication Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
TABLE 190: Rest of Europe 16-Year Perspective for Cutaneous and Systemic Leishmaniasis by Indication - Percentage Breakdown of Value Sales for Cutaneous Leishmaniasis Indication, Mucosal Leishmaniasis Indication and Visceral Leishmaniasis Indication for the Years 2014, 2025 & 2030
ASIA-PACIFIC
Cutaneous and Systemic Leishmaniasis Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
TABLE 191: Asia-Pacific Recent Past, Current & Future Analysis for Cutaneous and Systemic Leishmaniasis by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
TABLE 192: Asia-Pacific Historic Review for Cutaneous and Systemic Leishmaniasis by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
TABLE 193: Asia-Pacific 16-Year Perspective for Cutaneous and Systemic Leishmaniasis by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2014, 2025 & 2030
TABLE 194: Asia-Pacific Recent Past, Current & Future Analysis for Cutaneous and Systemic Leishmaniasis by Drug Class - Pentavalent Antimonials Drug Class, Antifungals Drug Class and Anti-Lesihmanial / Antimicrobials Drug Class - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 195: Asia-Pacific Historic Review for Cutaneous and Systemic Leishmaniasis by Drug Class - Pentavalent Antimonials Drug Class, Antifungals Drug Class and Anti-Lesihmanial / Antimicrobials Drug Class Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
TABLE 196: Asia-Pacific 16-Year Perspective for Cutaneous and Systemic Leishmaniasis by Drug Class - Percentage Breakdown of Value Sales for Pentavalent Antimonials Drug Class, Antifungals Drug Class and Anti-Lesihmanial / Antimicrobials Drug Class for the Years 2014, 2025 & 2030
TABLE 197: Asia-Pacific Recent Past, Current & Future Analysis for Cutaneous and Systemic Leishmaniasis by Distribution Channel - Hospital Pharmacies, Retail Pharmacies, Drug Stores and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 198: Asia-Pacific Historic Review for Cutaneous and Systemic Leishmaniasis by Distribution Channel - Hospital Pharmacies, Retail Pharmacies, Drug Stores and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
TABLE 199: Asia-Pacific 16-Year Perspective for Cutaneous and Systemic Leishmaniasis by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies, Drug Stores and Online Distribution Channel for the Years 2014, 2025 & 2030
TABLE 200: Asia-Pacific Recent Past, Current & Future Analysis for Cutaneous and Systemic Leishmaniasis by Administration Route - Oral Route, Injectable Route and Topical Route - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 201: Asia-Pacific Historic Review for Cutaneous and Systemic Leishmaniasis by Administration Route - Oral Route, Injectable Route and Topical Route Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
TABLE 202: Asia-Pacific 16-Year Perspective for Cutaneous and Systemic Leishmaniasis by Administration Route - Percentage Breakdown of Value Sales for Oral Route, Injectable Route and Topical Route for the Years 2014, 2025 & 2030
TABLE 203: Asia-Pacific Recent Past, Current & Future Analysis for Cutaneous and Systemic Leishmaniasis by Indication - Cutaneous Leishmaniasis Indication, Mucosal Leishmaniasis Indication and Visceral Leishmaniasis Indication - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 204: Asia-Pacific Historic Review for Cutaneous and Systemic Leishmaniasis by Indication - Cutaneous Leishmaniasis Indication, Mucosal Leishmaniasis Indication and Visceral Leishmaniasis Indication Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
TABLE 205: Asia-Pacific 16-Year Perspective for Cutaneous and Systemic Leishmaniasis by Indication - Percentage Breakdown of Value Sales for Cutaneous Leishmaniasis Indication, Mucosal Leishmaniasis Indication and Visceral Leishmaniasis Indication for the Years 2014, 2025 & 2030
AUSTRALIA
Cutaneous and Systemic Leishmaniasis Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
TABLE 206: Australia Recent Past, Current & Future Analysis for Cutaneous and Systemic Leishmaniasis by Drug Class - Pentavalent Antimonials Drug Class, Antifungals Drug Class and Anti-Lesihmanial / Antimicrobials Drug Class - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 207: Australia Historic Review for Cutaneous and Systemic Leishmaniasis by Drug Class - Pentavalent Antimonials Drug Class, Antifungals Drug Class and Anti-Lesihmanial / Antimicrobials Drug Class Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
TABLE 208: Australia 16-Year Perspective for Cutaneous and Systemic Leishmaniasis by Drug Class - Percentage Breakdown of Value Sales for Pentavalent Antimonials Drug Class, Antifungals Drug Class and Anti-Lesihmanial / Antimicrobials Drug Class for the Years 2014, 2025 & 2030
TABLE 209: Australia Recent Past, Current & Future Analysis for Cutaneous and Systemic Leishmaniasis by Distribution Channel - Hospital Pharmacies, Retail Pharmacies, Drug Stores and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 210: Australia Historic Review for Cutaneous and Systemic Leishmaniasis by Distribution Channel - Hospital Pharmacies, Retail Pharmacies, Drug Stores and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
TABLE 211: Australia 16-Year Perspective for Cutaneous and Systemic Leishmaniasis by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies, Drug Stores and Online Distribution Channel for the Years 2014, 2025 & 2030
TABLE 212: Australia Recent Past, Current & Future Analysis for Cutaneous and Systemic Leishmaniasis by Administration Route - Oral Route, Injectable Route and Topical Route - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 213: Australia Historic Review for Cutaneous and Systemic Leishmaniasis by Administration Route - Oral Route, Injectable Route and Topical Route Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
TABLE 214: Australia 16-Year Perspective for Cutaneous and Systemic Leishmaniasis by Administration Route - Percentage Breakdown of Value Sales for Oral Route, Injectable Route and Topical Route for the Years 2014, 2025 & 2030
TABLE 215: Australia Recent Past, Current & Future Analysis for Cutaneous and Systemic Leishmaniasis by Indication - Cutaneous Leishmaniasis Indication, Mucosal Leishmaniasis Indication and Visceral Leishmaniasis Indication - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 216: Australia Historic Review for Cutaneous and Systemic Leishmaniasis by Indication - Cutaneous Leishmaniasis Indication, Mucosal Leishmaniasis Indication and Visceral Leishmaniasis Indication Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
TABLE 217: Australia 16-Year Perspective for Cutaneous and Systemic Leishmaniasis by Indication - Percentage Breakdown of Value Sales for Cutaneous Leishmaniasis Indication, Mucosal Leishmaniasis Indication and Visceral Leishmaniasis Indication for the Years 2014, 2025 & 2030
INDIA
Cutaneous and Systemic Leishmaniasis Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
TABLE 218: India Recent Past, Current & Future Analysis for Cutaneous and Systemic Leishmaniasis by Drug Class - Pentavalent Antimonials Drug Class, Antifungals Drug Class and Anti-Lesihmanial / Antimicrobials Drug Class - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 219: India Historic Review for Cutaneous and Systemic Leishmaniasis by Drug Class - Pentavalent Antimonials Drug Class, Antifungals Drug Class and Anti-Lesihmanial / Antimicrobials Drug Class Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
TABLE 220: India 16-Year Perspective for Cutaneous and Systemic Leishmaniasis by Drug Class - Percentage Breakdown of Value Sales for Pentavalent Antimonials Drug Class, Antifungals Drug Class and Anti-Lesihmanial / Antimicrobials Drug Class for the Years 2014, 2025 & 2030
TABLE 221: India Recent Past, Current & Future Analysis for Cutaneous and Systemic Leishmaniasis by Distribution Channel - Hospital Pharmacies, Retail Pharmacies, Drug Stores and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 222: India Historic Review for Cutaneous and Systemic Leishmaniasis by Distribution Channel - Hospital Pharmacies, Retail Pharmacies, Drug Stores and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
TABLE 223: India 16-Year Perspective for Cutaneous and Systemic Leishmaniasis by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies, Drug Stores and Online Distribution Channel for the Years 2014, 2025 & 2030
TABLE 224: India Recent Past, Current & Future Analysis for Cutaneous and Systemic Leishmaniasis by Administration Route - Oral Route, Injectable Route and Topical Route - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 225: India Historic Review for Cutaneous and Systemic Leishmaniasis by Administration Route - Oral Route, Injectable Route and Topical Route Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
TABLE 226: India 16-Year Perspective for Cutaneous and Systemic Leishmaniasis by Administration Route - Percentage Breakdown of Value Sales for Oral Route, Injectable Route and Topical Route for the Years 2014, 2025 & 2030
TABLE 227: India Recent Past, Current & Future Analysis for Cutaneous and Systemic Leishmaniasis by Indication - Cutaneous Leishmaniasis Indication, Mucosal Leishmaniasis Indication and Visceral Leishmaniasis Indication - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 228: India Historic Review for Cutaneous and Systemic Leishmaniasis by Indication - Cutaneous Leishmaniasis Indication, Mucosal Leishmaniasis Indication and Visceral Leishmaniasis Indication Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
TABLE 229: India 16-Year Perspective for Cutaneous and Systemic Leishmaniasis by Indication - Percentage Breakdown of Value Sales for Cutaneous Leishmaniasis Indication, Mucosal Leishmaniasis Indication and Visceral Leishmaniasis Indication for the Years 2014, 2025 & 2030
SOUTH KOREA
TABLE 230: South Korea Recent Past, Current & Future Analysis for Cutaneous and Systemic Leishmaniasis by Drug Class - Pentavalent Antimonials Drug Class, Antifungals Drug Class and Anti-Lesihmanial / Antimicrobials Drug Class - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 231: South Korea Historic Review for Cutaneous and Systemic Leishmaniasis by Drug Class - Pentavalent Antimonials Drug Class, Antifungals Drug Class and Anti-Lesihmanial / Antimicrobials Drug Class Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
TABLE 232: South Korea 16-Year Perspective for Cutaneous and Systemic Leishmaniasis by Drug Class - Percentage Breakdown of Value Sales for Pentavalent Antimonials Drug Class, Antifungals Drug Class and Anti-Lesihmanial / Antimicrobials Drug Class for the Years 2014, 2025 & 2030
TABLE 233: South Korea Recent Past, Current & Future Analysis for Cutaneous and Systemic Leishmaniasis by Distribution Channel - Hospital Pharmacies, Retail Pharmacies, Drug Stores and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 234: South Korea Historic Review for Cutaneous and Systemic Leishmaniasis by Distribution Channel - Hospital Pharmacies, Retail Pharmacies, Drug Stores and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
TABLE 235: South Korea 16-Year Perspective for Cutaneous and Systemic Leishmaniasis by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies, Drug Stores and Online Distribution Channel for the Years 2014, 2025 & 2030
TABLE 236: South Korea Recent Past, Current & Future Analysis for Cutaneous and Systemic Leishmaniasis by Administration Route - Oral Route, Injectable Route and Topical Route - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 237: South Korea Historic Review for Cutaneous and Systemic Leishmaniasis by Administration Route - Oral Route, Injectable Route and Topical Route Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
TABLE 238: South Korea 16-Year Perspective for Cutaneous and Systemic Leishmaniasis by Administration Route - Percentage Breakdown of Value Sales for Oral Route, Injectable Route and Topical Route for the Years 2014, 2025 & 2030
TABLE 239: South Korea Recent Past, Current & Future Analysis for Cutaneous and Systemic Leishmaniasis by Indication - Cutaneous Leishmaniasis Indication, Mucosal Leishmaniasis Indication and Visceral Leishmaniasis Indication - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 240: South Korea Historic Review for Cutaneous and Systemic Leishmaniasis by Indication - Cutaneous Leishmaniasis Indication, Mucosal Leishmaniasis Indication and Visceral Leishmaniasis Indication Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
TABLE 241: South Korea 16-Year Perspective for Cutaneous and Systemic Leishmaniasis by Indication - Percentage Breakdown of Value Sales for Cutaneous Leishmaniasis Indication, Mucosal Leishmaniasis Indication and Visceral Leishmaniasis Indication for the Years 2014, 2025 & 2030
REST OF ASIA-PACIFIC
TABLE 242: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Cutaneous and Systemic Leishmaniasis by Drug Class - Pentavalent Antimonials Drug Class, Antifungals Drug Class and Anti-Lesihmanial / Antimicrobials Drug Class - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 243: Rest of Asia-Pacific Historic Review for Cutaneous and Systemic Leishmaniasis by Drug Class - Pentavalent Antimonials Drug Class, Antifungals Drug Class and Anti-Lesihmanial / Antimicrobials Drug Class Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
TABLE 244: Rest of Asia-Pacific 16-Year Perspective for Cutaneous and Systemic Leishmaniasis by Drug Class - Percentage Breakdown of Value Sales for Pentavalent Antimonials Drug Class, Antifungals Drug Class and Anti-Lesihmanial / Antimicrobials Drug Class for the Years 2014, 2025 & 2030
TABLE 245: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Cutaneous and Systemic Leishmaniasis by Distribution Channel - Hospital Pharmacies, Retail Pharmacies, Drug Stores and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 246: Rest of Asia-Pacific Historic Review for Cutaneous and Systemic Leishmaniasis by Distribution Channel - Hospital Pharmacies, Retail Pharmacies, Drug Stores and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
TABLE 247: Rest of Asia-Pacific 16-Year Perspective for Cutaneous and Systemic Leishmaniasis by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies, Drug Stores and Online Distribution Channel for the Years 2014, 2025 & 2030
TABLE 248: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Cutaneous and Systemic Leishmaniasis by Administration Route - Oral Route, Injectable Route and Topical Route - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 249: Rest of Asia-Pacific Historic Review for Cutaneous and Systemic Leishmaniasis by Administration Route - Oral Route, Injectable Route and Topical Route Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
TABLE 250: Rest of Asia-Pacific 16-Year Perspective for Cutaneous and Systemic Leishmaniasis by Administration Route - Percentage Breakdown of Value Sales for Oral Route, Injectable Route and Topical Route for the Years 2014, 2025 & 2030
TABLE 251: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Cutaneous and Systemic Leishmaniasis by Indication - Cutaneous Leishmaniasis Indication, Mucosal Leishmaniasis Indication and Visceral Leishmaniasis Indication - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 252: Rest of Asia-Pacific Historic Review for Cutaneous and Systemic Leishmaniasis by Indication - Cutaneous Leishmaniasis Indication, Mucosal Leishmaniasis Indication and Visceral Leishmaniasis Indication Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
TABLE 253: Rest of Asia-Pacific 16-Year Perspective for Cutaneous and Systemic Leishmaniasis by Indication - Percentage Breakdown of Value Sales for Cutaneous Leishmaniasis Indication, Mucosal Leishmaniasis Indication and Visceral Leishmaniasis Indication for the Years 2014, 2025 & 2030
LATIN AMERICA
Cutaneous and Systemic Leishmaniasis Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
TABLE 254: Latin America Recent Past, Current & Future Analysis for Cutaneous and Systemic Leishmaniasis by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
TABLE 255: Latin America Historic Review for Cutaneous and Systemic Leishmaniasis by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
TABLE 256: Latin America 16-Year Perspective for Cutaneous and Systemic Leishmaniasis by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2014, 2025 & 2030
TABLE 257: Latin America Recent Past, Current & Future Analysis for Cutaneous and Systemic Leishmaniasis by Drug Class - Pentavalent Antimonials Drug Class, Antifungals Drug Class and Anti-Lesihmanial / Antimicrobials Drug Class - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 258: Latin America Historic Review for Cutaneous and Systemic Leishmaniasis by Drug Class - Pentavalent Antimonials Drug Class, Antifungals Drug Class and Anti-Lesihmanial / Antimicrobials Drug Class Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
TABLE 259: Latin America 16-Year Perspective for Cutaneous and Systemic Leishmaniasis by Drug Class - Percentage Breakdown of Value Sales for Pentavalent Antimonials Drug Class, Antifungals Drug Class and Anti-Lesihmanial / Antimicrobials Drug Class for the Years 2014, 2025 & 2030
TABLE 260: Latin America Recent Past, Current & Future Analysis for Cutaneous and Systemic Leishmaniasis by Distribution Channel - Hospital Pharmacies, Retail Pharmacies, Drug Stores and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 261: Latin America Historic Review for Cutaneous and Systemic Leishmaniasis by Distribution Channel - Hospital Pharmacies, Retail Pharmacies, Drug Stores and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
TABLE 262: Latin America 16-Year Perspective for Cutaneous and Systemic Leishmaniasis by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies, Drug Stores and Online Distribution Channel for the Years 2014, 2025 & 2030
TABLE 263: Latin America Recent Past, Current & Future Analysis for Cutaneous and Systemic Leishmaniasis by Administration Route - Oral Route, Injectable Route and Topical Route - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 264: Latin America Historic Review for Cutaneous and Systemic Leishmaniasis by Administration Route - Oral Route, Injectable Route and Topical Route Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
TABLE 265: Latin America 16-Year Perspective for Cutaneous and Systemic Leishmaniasis by Administration Route - Percentage Breakdown of Value Sales for Oral Route, Injectable Route and Topical Route for the Years 2014, 2025 & 2030
TABLE 266: Latin America Recent Past, Current & Future Analysis for Cutaneous and Systemic Leishmaniasis by Indication - Cutaneous Leishmaniasis Indication, Mucosal Leishmaniasis Indication and Visceral Leishmaniasis Indication - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 267: Latin America Historic Review for Cutaneous and Systemic Leishmaniasis by Indication - Cutaneous Leishmaniasis Indication, Mucosal Leishmaniasis Indication and Visceral Leishmaniasis Indication Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
TABLE 268: Latin America 16-Year Perspective for Cutaneous and Systemic Leishmaniasis by Indication - Percentage Breakdown of Value Sales for Cutaneous Leishmaniasis Indication, Mucosal Leishmaniasis Indication and Visceral Leishmaniasis Indication for the Years 2014, 2025 & 2030
ARGENTINA
TABLE 269: Argentina Recent Past, Current & Future Analysis for Cutaneous and Systemic Leishmaniasis by Drug Class - Pentavalent Antimonials Drug Class, Antifungals Drug Class and Anti-Lesihmanial / Antimicrobials Drug Class - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 270: Argentina Historic Review for Cutaneous and Systemic Leishmaniasis by Drug Class - Pentavalent Antimonials Drug Class, Antifungals Drug Class and Anti-Lesihmanial / Antimicrobials Drug Class Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
TABLE 271: Argentina 16-Year Perspective for Cutaneous and Systemic Leishmaniasis by Drug Class - Percentage Breakdown of Value Sales for Pentavalent Antimonials Drug Class, Antifungals Drug Class and Anti-Lesihmanial / Antimicrobials Drug Class for the Years 2014, 2025 & 2030
TABLE 272: Argentina Recent Past, Current & Future Analysis for Cutaneous and Systemic Leishmaniasis by Distribution Channel - Hospital Pharmacies, Retail Pharmacies, Drug Stores and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 273: Argentina Historic Review for Cutaneous and Systemic Leishmaniasis by Distribution Channel - Hospital Pharmacies, Retail Pharmacies, Drug Stores and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
TABLE 274: Argentina 16-Year Perspective for Cutaneous and Systemic Leishmaniasis by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies, Drug Stores and Online Distribution Channel for the Years 2014, 2025 & 2030
TABLE 275: Argentina Recent Past, Current & Future Analysis for Cutaneous and Systemic Leishmaniasis by Administration Route - Oral Route, Injectable Route and Topical Route - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 276: Argentina Historic Review for Cutaneous and Systemic Leishmaniasis by Administration Route - Oral Route, Injectable Route and Topical Route Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
TABLE 277: Argentina 16-Year Perspective for Cutaneous and Systemic Leishmaniasis by Administration Route - Percentage Breakdown of Value Sales for Oral Route, Injectable Route and Topical Route for the Years 2014, 2025 & 2030
TABLE 278: Argentina Recent Past, Current & Future Analysis for Cutaneous and Systemic Leishmaniasis by Indication - Cutaneous Leishmaniasis Indication, Mucosal Leishmaniasis Indication and Visceral Leishmaniasis Indication - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 279: Argentina Historic Review for Cutaneous and Systemic Leishmaniasis by Indication - Cutaneous Leishmaniasis Indication, Mucosal Leishmaniasis Indication and Visceral Leishmaniasis Indication Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
TABLE 280: Argentina 16-Year Perspective for Cutaneous and Systemic Leishmaniasis by Indication - Percentage Breakdown of Value Sales for Cutaneous Leishmaniasis Indication, Mucosal Leishmaniasis Indication and Visceral Leishmaniasis Indication for the Years 2014, 2025 & 2030
BRAZIL
TABLE 281: Brazil Recent Past, Current & Future Analysis for Cutaneous and Systemic Leishmaniasis by Drug Class - Pentavalent Antimonials Drug Class, Antifungals Drug Class and Anti-Lesihmanial / Antimicrobials Drug Class - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 282: Brazil Historic Review for Cutaneous and Systemic Leishmaniasis by Drug Class - Pentavalent Antimonials Drug Class, Antifungals Drug Class and Anti-Lesihmanial / Antimicrobials Drug Class Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
TABLE 283: Brazil 16-Year Perspective for Cutaneous and Systemic Leishmaniasis by Drug Class - Percentage Breakdown of Value Sales for Pentavalent Antimonials Drug Class, Antifungals Drug Class and Anti-Lesihmanial / Antimicrobials Drug Class for the Years 2014, 2025 & 2030
TABLE 284: Brazil Recent Past, Current & Future Analysis for Cutaneous and Systemic Leishmaniasis by Distribution Channel - Hospital Pharmacies, Retail Pharmacies, Drug Stores and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 285: Brazil Historic Review for Cutaneous and Systemic Leishmaniasis by Distribution Channel - Hospital Pharmacies, Retail Pharmacies, Drug Stores and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
TABLE 286: Brazil 16-Year Perspective for Cutaneous and Systemic Leishmaniasis by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies, Drug Stores and Online Distribution Channel for the Years 2014, 2025 & 2030
TABLE 287: Brazil Recent Past, Current & Future Analysis for Cutaneous and Systemic Leishmaniasis by Administration Route - Oral Route, Injectable Route and Topical Route - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 288: Brazil Historic Review for Cutaneous and Systemic Leishmaniasis by Administration Route - Oral Route, Injectable Route and Topical Route Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
TABLE 289: Brazil 16-Year Perspective for Cutaneous and Systemic Leishmaniasis by Administration Route - Percentage Breakdown of Value Sales for Oral Route, Injectable Route and Topical Route for the Years 2014, 2025 & 2030
TABLE 290: Brazil Recent Past, Current & Future Analysis for Cutaneous and Systemic Leishmaniasis by Indication - Cutaneous Leishmaniasis Indication, Mucosal Leishmaniasis Indication and Visceral Leishmaniasis Indication - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 291: Brazil Historic Review for Cutaneous and Systemic Leishmaniasis by Indication - Cutaneous Leishmaniasis Indication, Mucosal Leishmaniasis Indication and Visceral Leishmaniasis Indication Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
TABLE 292: Brazil 16-Year Perspective for Cutaneous and Systemic Leishmaniasis by Indication - Percentage Breakdown of Value Sales for Cutaneous Leishmaniasis Indication, Mucosal Leishmaniasis Indication and Visceral Leishmaniasis Indication for the Years 2014, 2025 & 2030
MEXICO
TABLE 293: Mexico Recent Past, Current & Future Analysis for Cutaneous and Systemic Leishmaniasis by Drug Class - Pentavalent Antimonials Drug Class, Antifungals Drug Class and Anti-Lesihmanial / Antimicrobials Drug Class - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 294: Mexico Historic Review for Cutaneous and Systemic Leishmaniasis by Drug Class - Pentavalent Antimonials Drug Class, Antifungals Drug Class and Anti-Lesihmanial / Antimicrobials Drug Class Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
TABLE 295: Mexico 16-Year Perspective for Cutaneous and Systemic Leishmaniasis by Drug Class - Percentage Breakdown of Value Sales for Pentavalent Antimonials Drug Class, Antifungals Drug Class and Anti-Lesihmanial / Antimicrobials Drug Class for the Years 2014, 2025 & 2030
TABLE 296: Mexico Recent Past, Current & Future Analysis for Cutaneous and Systemic Leishmaniasis by Distribution Channel - Hospital Pharmacies, Retail Pharmacies, Drug Stores and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 297: Mexico Historic Review for Cutaneous and Systemic Leishmaniasis by Distribution Channel - Hospital Pharmacies, Retail Pharmacies, Drug Stores and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
TABLE 298: Mexico 16-Year Perspective for Cutaneous and Systemic Leishmaniasis by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies, Drug Stores and Online Distribution Channel for the Years 2014, 2025 & 2030
TABLE 299: Mexico Recent Past, Current & Future Analysis for Cutaneous and Systemic Leishmaniasis by Administration Route - Oral Route, Injectable Route and Topical Route - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 300: Mexico Historic Review for Cutaneous and Systemic Leishmaniasis by Administration Route - Oral Route, Injectable Route and Topical Route Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
TABLE 301: Mexico 16-Year Perspective for Cutaneous and Systemic Leishmaniasis by Administration Route - Percentage Breakdown of Value Sales for Oral Route, Injectable Route and Topical Route for the Years 2014, 2025 & 2030
TABLE 302: Mexico Recent Past, Current & Future Analysis for Cutaneous and Systemic Leishmaniasis by Indication - Cutaneous Leishmaniasis Indication, Mucosal Leishmaniasis Indication and Visceral Leishmaniasis Indication - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 303: Mexico Historic Review for Cutaneous and Systemic Leishmaniasis by Indication - Cutaneous Leishmaniasis Indication, Mucosal Leishmaniasis Indication and Visceral Leishmaniasis Indication Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
TABLE 304: Mexico 16-Year Perspective for Cutaneous and Systemic Leishmaniasis by Indication - Percentage Breakdown of Value Sales for Cutaneous Leishmaniasis Indication, Mucosal Leishmaniasis Indication and Visceral Leishmaniasis Indication for the Years 2014, 2025 & 2030
REST OF LATIN AMERICA
TABLE 305: Rest of Latin America Recent Past, Current & Future Analysis for Cutaneous and Systemic Leishmaniasis by Drug Class - Pentavalent Antimonials Drug Class, Antifungals Drug Class and Anti-Lesihmanial / Antimicrobials Drug Class - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 306: Rest of Latin America Historic Review for Cutaneous and Systemic Leishmaniasis by Drug Class - Pentavalent Antimonials Drug Class, Antifungals Drug Class and Anti-Lesihmanial / Antimicrobials Drug Class Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
TABLE 307: Rest of Latin America 16-Year Perspective for Cutaneous and Systemic Leishmaniasis by Drug Class - Percentage Breakdown of Value Sales for Pentavalent Antimonials Drug Class, Antifungals Drug Class and Anti-Lesihmanial / Antimicrobials Drug Class for the Years 2014, 2025 & 2030
TABLE 308: Rest of Latin America Recent Past, Current & Future Analysis for Cutaneous and Systemic Leishmaniasis by Distribution Channel - Hospital Pharmacies, Retail Pharmacies, Drug Stores and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 309: Rest of Latin America Historic Review for Cutaneous and Systemic Leishmaniasis by Distribution Channel - Hospital Pharmacies, Retail Pharmacies, Drug Stores and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
TABLE 310: Rest of Latin America 16-Year Perspective for Cutaneous and Systemic Leishmaniasis by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies, Drug Stores and Online Distribution Channel for the Years 2014, 2025 & 2030
TABLE 311: Rest of Latin America Recent Past, Current & Future Analysis for Cutaneous and Systemic Leishmaniasis by Administration Route - Oral Route, Injectable Route and Topical Route - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 312: Rest of Latin America Historic Review for Cutaneous and Systemic Leishmaniasis by Administration Route - Oral Route, Injectable Route and Topical Route Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
TABLE 313: Rest of Latin America 16-Year Perspective for Cutaneous and Systemic Leishmaniasis by Administration Route - Percentage Breakdown of Value Sales for Oral Route, Injectable Route and Topical Route for the Years 2014, 2025 & 2030
TABLE 314: Rest of Latin America Recent Past, Current & Future Analysis for Cutaneous and Systemic Leishmaniasis by Indication - Cutaneous Leishmaniasis Indication, Mucosal Leishmaniasis Indication and Visceral Leishmaniasis Indication - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 315: Rest of Latin America Historic Review for Cutaneous and Systemic Leishmaniasis by Indication - Cutaneous Leishmaniasis Indication, Mucosal Leishmaniasis Indication and Visceral Leishmaniasis Indication Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
TABLE 316: Rest of Latin America 16-Year Perspective for Cutaneous and Systemic Leishmaniasis by Indication - Percentage Breakdown of Value Sales for Cutaneous Leishmaniasis Indication, Mucosal Leishmaniasis Indication and Visceral Leishmaniasis Indication for the Years 2014, 2025 & 2030
MIDDLE EAST
Cutaneous and Systemic Leishmaniasis Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
TABLE 317: Middle East Recent Past, Current & Future Analysis for Cutaneous and Systemic Leishmaniasis by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
TABLE 318: Middle East Historic Review for Cutaneous and Systemic Leishmaniasis by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
TABLE 319: Middle East 16-Year Perspective for Cutaneous and Systemic Leishmaniasis by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2014, 2025 & 2030
TABLE 320: Middle East Recent Past, Current & Future Analysis for Cutaneous and Systemic Leishmaniasis by Drug Class - Pentavalent Antimonials Drug Class, Antifungals Drug Class and Anti-Lesihmanial / Antimicrobials Drug Class - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 321: Middle East Historic Review for Cutaneous and Systemic Leishmaniasis by Drug Class - Pentavalent Antimonials Drug Class, Antifungals Drug Class and Anti-Lesihmanial / Antimicrobials Drug Class Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
TABLE 322: Middle East 16-Year Perspective for Cutaneous and Systemic Leishmaniasis by Drug Class - Percentage Breakdown of Value Sales for Pentavalent Antimonials Drug Class, Antifungals Drug Class and Anti-Lesihmanial / Antimicrobials Drug Class for the Years 2014, 2025 & 2030
TABLE 323: Middle East Recent Past, Current & Future Analysis for Cutaneous and Systemic Leishmaniasis by Distribution Channel - Hospital Pharmacies, Retail Pharmacies, Drug Stores and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 324: Middle East Historic Review for Cutaneous and Systemic Leishmaniasis by Distribution Channel - Hospital Pharmacies, Retail Pharmacies, Drug Stores and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
TABLE 325: Middle East 16-Year Perspective for Cutaneous and Systemic Leishmaniasis by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies, Drug Stores and Online Distribution Channel for the Years 2014, 2025 & 2030
TABLE 326: Middle East Recent Past, Current & Future Analysis for Cutaneous and Systemic Leishmaniasis by Administration Route - Oral Route, Injectable Route and Topical Route - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 327: Middle East Historic Review for Cutaneous and Systemic Leishmaniasis by Administration Route - Oral Route, Injectable Route and Topical Route Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
TABLE 328: Middle East 16-Year Perspective for Cutaneous and Systemic Leishmaniasis by Administration Route - Percentage Breakdown of Value Sales for Oral Route, Injectable Route and Topical Route for the Years 2014, 2025 & 2030
TABLE 329: Middle East Recent Past, Current & Future Analysis for Cutaneous and Systemic Leishmaniasis by Indication - Cutaneous Leishmaniasis Indication, Mucosal Leishmaniasis Indication and Visceral Leishmaniasis Indication - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 330: Middle East Historic Review for Cutaneous and Systemic Leishmaniasis by Indication - Cutaneous Leishmaniasis Indication, Mucosal Leishmaniasis Indication and Visceral Leishmaniasis Indication Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
TABLE 331: Middle East 16-Year Perspective for Cutaneous and Systemic Leishmaniasis by Indication - Percentage Breakdown of Value Sales for Cutaneous Leishmaniasis Indication, Mucosal Leishmaniasis Indication and Visceral Leishmaniasis Indication for the Years 2014, 2025 & 2030
IRAN
TABLE 332: Iran Recent Past, Current & Future Analysis for Cutaneous and Systemic Leishmaniasis by Drug Class - Pentavalent Antimonials Drug Class, Antifungals Drug Class and Anti-Lesihmanial / Antimicrobials Drug Class - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 333: Iran Historic Review for Cutaneous and Systemic Leishmaniasis by Drug Class - Pentavalent Antimonials Drug Class, Antifungals Drug Class and Anti-Lesihmanial / Antimicrobials Drug Class Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
TABLE 334: Iran 16-Year Perspective for Cutaneous and Systemic Leishmaniasis by Drug Class - Percentage Breakdown of Value Sales for Pentavalent Antimonials Drug Class, Antifungals Drug Class and Anti-Lesihmanial / Antimicrobials Drug Class for the Years 2014, 2025 & 2030
TABLE 335: Iran Recent Past, Current & Future Analysis for Cutaneous and Systemic Leishmaniasis by Distribution Channel - Hospital Pharmacies, Retail Pharmacies, Drug Stores and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 336: Iran Historic Review for Cutaneous and Systemic Leishmaniasis by Distribution Channel - Hospital Pharmacies, Retail Pharmacies, Drug Stores and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
TABLE 337: Iran 16-Year Perspective for Cutaneous and Systemic Leishmaniasis by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies, Drug Stores and Online Distribution Channel for the Years 2014, 2025 & 2030
TABLE 338: Iran Recent Past, Current & Future Analysis for Cutaneous and Systemic Leishmaniasis by Administration Route - Oral Route, Injectable Route and Topical Route - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 339: Iran Historic Review for Cutaneous and Systemic Leishmaniasis by Administration Route - Oral Route, Injectable Route and Topical Route Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
TABLE 340: Iran 16-Year Perspective for Cutaneous and Systemic Leishmaniasis by Administration Route - Percentage Breakdown of Value Sales for Oral Route, Injectable Route and Topical Route for the Years 2014, 2025 & 2030
TABLE 341: Iran Recent Past, Current & Future Analysis for Cutaneous and Systemic Leishmaniasis by Indication - Cutaneous Leishmaniasis Indication, Mucosal Leishmaniasis Indication and Visceral Leishmaniasis Indication - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 342: Iran Historic Review for Cutaneous and Systemic Leishmaniasis by Indication - Cutaneous Leishmaniasis Indication, Mucosal Leishmaniasis Indication and Visceral Leishmaniasis Indication Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
TABLE 343: Iran 16-Year Perspective for Cutaneous and Systemic Leishmaniasis by Indication - Percentage Breakdown of Value Sales for Cutaneous Leishmaniasis Indication, Mucosal Leishmaniasis Indication and Visceral Leishmaniasis Indication for the Years 2014, 2025 & 2030
ISRAEL
TABLE 344: Israel Recent Past, Current & Future Analysis for Cutaneous and Systemic Leishmaniasis by Drug Class - Pentavalent Antimonials Drug Class, Antifungals Drug Class and Anti-Lesihmanial / Antimicrobials Drug Class - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 345: Israel Historic Review for Cutaneous and Systemic Leishmaniasis by Drug Class - Pentavalent Antimonials Drug Class, Antifungals Drug Class and Anti-Lesihmanial / Antimicrobials Drug Class Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
TABLE 346: Israel 16-Year Perspective for Cutaneous and Systemic Leishmaniasis by Drug Class - Percentage Breakdown of Value Sales for Pentavalent Antimonials Drug Class, Antifungals Drug Class and Anti-Lesihmanial / Antimicrobials Drug Class for the Years 2014, 2025 & 2030
TABLE 347: Israel Recent Past, Current & Future Analysis for Cutaneous and Systemic Leishmaniasis by Distribution Channel - Hospital Pharmacies, Retail Pharmacies, Drug Stores and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 348: Israel Historic Review for Cutaneous and Systemic Leishmaniasis by Distribution Channel - Hospital Pharmacies, Retail Pharmacies, Drug Stores and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
TABLE 349: Israel 16-Year Perspective for Cutaneous and Systemic Leishmaniasis by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies, Drug Stores and Online Distribution Channel for the Years 2014, 2025 & 2030
TABLE 350: Israel Recent Past, Current & Future Analysis for Cutaneous and Systemic Leishmaniasis by Administration Route - Oral Route, Injectable Route and Topical Route - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 351: Israel Historic Review for Cutaneous and Systemic Leishmaniasis by Administration Route - Oral Route, Injectable Route and Topical Route Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
TABLE 352: Israel 16-Year Perspective for Cutaneous and Systemic Leishmaniasis by Administration Route - Percentage Breakdown of Value Sales for Oral Route, Injectable Route and Topical Route for the Years 2014, 2025 & 2030
TABLE 353: Israel Recent Past, Current & Future Analysis for Cutaneous and Systemic Leishmaniasis by Indication - Cutaneous Leishmaniasis Indication, Mucosal Leishmaniasis Indication and Visceral Leishmaniasis Indication - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 354: Israel Historic Review for Cutaneous and Systemic Leishmaniasis by Indication - Cutaneous Leishmaniasis Indication, Mucosal Leishmaniasis Indication and Visceral Leishmaniasis Indication Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
TABLE 355: Israel 16-Year Perspective for Cutaneous and Systemic Leishmaniasis by Indication - Percentage Breakdown of Value Sales for Cutaneous Leishmaniasis Indication, Mucosal Leishmaniasis Indication and Visceral Leishmaniasis Indication for the Years 2014, 2025 & 2030
SAUDI ARABIA
TABLE 356: Saudi Arabia Recent Past, Current & Future Analysis for Cutaneous and Systemic Leishmaniasis by Drug Class - Pentavalent Antimonials Drug Class, Antifungals Drug Class and Anti-Lesihmanial / Antimicrobials Drug Class - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 357: Saudi Arabia Historic Review for Cutaneous and Systemic Leishmaniasis by Drug Class - Pentavalent Antimonials Drug Class, Antifungals Drug Class and Anti-Lesihmanial / Antimicrobials Drug Class Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
TABLE 358: Saudi Arabia 16-Year Perspective for Cutaneous and Systemic Leishmaniasis by Drug Class - Percentage Breakdown of Value Sales for Pentavalent Antimonials Drug Class, Antifungals Drug Class and Anti-Lesihmanial / Antimicrobials Drug Class for the Years 2014, 2025 & 2030
TABLE 359: Saudi Arabia Recent Past, Current & Future Analysis for Cutaneous and Systemic Leishmaniasis by Distribution Channel - Hospital Pharmacies, Retail Pharmacies, Drug Stores and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 360: Saudi Arabia Historic Review for Cutaneous and Systemic Leishmaniasis by Distribution Channel - Hospital Pharmacies, Retail Pharmacies, Drug Stores and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
TABLE 361: Saudi Arabia 16-Year Perspective for Cutaneous and Systemic Leishmaniasis by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies, Drug Stores and Online Distribution Channel for the Years 2014, 2025 & 2030
TABLE 362: Saudi Arabia Recent Past, Current & Future Analysis for Cutaneous and Systemic Leishmaniasis by Administration Route - Oral Route, Injectable Route and Topical Route - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 363: Saudi Arabia Historic Review for Cutaneous and Systemic Leishmaniasis by Administration Route - Oral Route, Injectable Route and Topical Route Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
TABLE 364: Saudi Arabia 16-Year Perspective for Cutaneous and Systemic Leishmaniasis by Administration Route - Percentage Breakdown of Value Sales for Oral Route, Injectable Route and Topical Route for the Years 2014, 2025 & 2030
TABLE 365: Saudi Arabia Recent Past, Current & Future Analysis for Cutaneous and Systemic Leishmaniasis by Indication - Cutaneous Leishmaniasis Indication, Mucosal Leishmaniasis Indication and Visceral Leishmaniasis Indication - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 366: Saudi Arabia Historic Review for Cutaneous and Systemic Leishmaniasis by Indication - Cutaneous Leishmaniasis Indication, Mucosal Leishmaniasis Indication and Visceral Leishmaniasis Indication Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
TABLE 367: Saudi Arabia 16-Year Perspective for Cutaneous and Systemic Leishmaniasis by Indication - Percentage Breakdown of Value Sales for Cutaneous Leishmaniasis Indication, Mucosal Leishmaniasis Indication and Visceral Leishmaniasis Indication for the Years 2014, 2025 & 2030
UNITED ARAB EMIRATES
TABLE 368: UAE Recent Past, Current & Future Analysis for Cutaneous and Systemic Leishmaniasis by Drug Class - Pentavalent Antimonials Drug Class, Antifungals Drug Class and Anti-Lesihmanial / Antimicrobials Drug Class - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 369: UAE Historic Review for Cutaneous and Systemic Leishmaniasis by Drug Class - Pentavalent Antimonials Drug Class, Antifungals Drug Class and Anti-Lesihmanial / Antimicrobials Drug Class Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
TABLE 370: UAE 16-Year Perspective for Cutaneous and Systemic Leishmaniasis by Drug Class - Percentage Breakdown of Value Sales for Pentavalent Antimonials Drug Class, Antifungals Drug Class and Anti-Lesihmanial / Antimicrobials Drug Class for the Years 2014, 2025 & 2030
TABLE 371: UAE Recent Past, Current & Future Analysis for Cutaneous and Systemic Leishmaniasis by Distribution Channel - Hospital Pharmacies, Retail Pharmacies, Drug Stores and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 372: UAE Historic Review for Cutaneous and Systemic Leishmaniasis by Distribution Channel - Hospital Pharmacies, Retail Pharmacies, Drug Stores and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
TABLE 373: UAE 16-Year Perspective for Cutaneous and Systemic Leishmaniasis by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies, Drug Stores and Online Distribution Channel for the Years 2014, 2025 & 2030
TABLE 374: UAE Recent Past, Current & Future Analysis for Cutaneous and Systemic Leishmaniasis by Administration Route - Oral Route, Injectable Route and Topical Route - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 375: UAE Historic Review for Cutaneous and Systemic Leishmaniasis by Administration Route - Oral Route, Injectable Route and Topical Route Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
TABLE 376: UAE 16-Year Perspective for Cutaneous and Systemic Leishmaniasis by Administration Route - Percentage Breakdown of Value Sales for Oral Route, Injectable Route and Topical Route for the Years 2014, 2025 & 2030
TABLE 377: UAE Recent Past, Current & Future Analysis for Cutaneous and Systemic Leishmaniasis by Indication - Cutaneous Leishmaniasis Indication, Mucosal Leishmaniasis Indication and Visceral Leishmaniasis Indication - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 378: UAE Historic Review for Cutaneous and Systemic Leishmaniasis by Indication - Cutaneous Leishmaniasis Indication, Mucosal Leishmaniasis Indication and Visceral Leishmaniasis Indication Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
TABLE 379: UAE 16-Year Perspective for Cutaneous and Systemic Leishmaniasis by Indication - Percentage Breakdown of Value Sales for Cutaneous Leishmaniasis Indication, Mucosal Leishmaniasis Indication and Visceral Leishmaniasis Indication for the Years 2014, 2025 & 2030
REST OF MIDDLE EAST
TABLE 380: Rest of Middle East Recent Past, Current & Future Analysis for Cutaneous and Systemic Leishmaniasis by Drug Class - Pentavalent Antimonials Drug Class, Antifungals Drug Class and Anti-Lesihmanial / Antimicrobials Drug Class - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 381: Rest of Middle East Historic Review for Cutaneous and Systemic Leishmaniasis by Drug Class - Pentavalent Antimonials Drug Class, Antifungals Drug Class and Anti-Lesihmanial / Antimicrobials Drug Class Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
TABLE 382: Rest of Middle East 16-Year Perspective for Cutaneous and Systemic Leishmaniasis by Drug Class - Percentage Breakdown of Value Sales for Pentavalent Antimonials Drug Class, Antifungals Drug Class and Anti-Lesihmanial / Antimicrobials Drug Class for the Years 2014, 2025 & 2030
TABLE 383: Rest of Middle East Recent Past, Current & Future Analysis for Cutaneous and Systemic Leishmaniasis by Distribution Channel - Hospital Pharmacies, Retail Pharmacies, Drug Stores and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 384: Rest of Middle East Historic Review for Cutaneous and Systemic Leishmaniasis by Distribution Channel - Hospital Pharmacies, Retail Pharmacies, Drug Stores and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
TABLE 385: Rest of Middle East 16-Year Perspective for Cutaneous and Systemic Leishmaniasis by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies, Drug Stores and Online Distribution Channel for the Years 2014, 2025 & 2030
TABLE 386: Rest of Middle East Recent Past, Current & Future Analysis for Cutaneous and Systemic Leishmaniasis by Administration Route - Oral Route, Injectable Route and Topical Route - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 387: Rest of Middle East Historic Review for Cutaneous and Systemic Leishmaniasis by Administration Route - Oral Route, Injectable Route and Topical Route Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
TABLE 388: Rest of Middle East 16-Year Perspective for Cutaneous and Systemic Leishmaniasis by Administration Route - Percentage Breakdown of Value Sales for Oral Route, Injectable Route and Topical Route for the Years 2014, 2025 & 2030
TABLE 389: Rest of Middle East Recent Past, Current & Future Analysis for Cutaneous and Systemic Leishmaniasis by Indication - Cutaneous Leishmaniasis Indication, Mucosal Leishmaniasis Indication and Visceral Leishmaniasis Indication - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 390: Rest of Middle East Historic Review for Cutaneous and Systemic Leishmaniasis by Indication - Cutaneous Leishmaniasis Indication, Mucosal Leishmaniasis Indication and Visceral Leishmaniasis Indication Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
TABLE 391: Rest of Middle East 16-Year Perspective for Cutaneous and Systemic Leishmaniasis by Indication - Percentage Breakdown of Value Sales for Cutaneous Leishmaniasis Indication, Mucosal Leishmaniasis Indication and Visceral Leishmaniasis Indication for the Years 2014, 2025 & 2030
AFRICA
Cutaneous and Systemic Leishmaniasis Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
TABLE 392: Africa Recent Past, Current & Future Analysis for Cutaneous and Systemic Leishmaniasis by Drug Class - Pentavalent Antimonials Drug Class, Antifungals Drug Class and Anti-Lesihmanial / Antimicrobials Drug Class - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 393: Africa Historic Review for Cutaneous and Systemic Leishmaniasis by Drug Class - Pentavalent Antimonials Drug Class, Antifungals Drug Class and Anti-Lesihmanial / Antimicrobials Drug Class Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
TABLE 394: Africa 16-Year Perspective for Cutaneous and Systemic Leishmaniasis by Drug Class - Percentage Breakdown of Value Sales for Pentavalent Antimonials Drug Class, Antifungals Drug Class and Anti-Lesihmanial / Antimicrobials Drug Class for the Years 2014, 2025 & 2030
TABLE 395: Africa Recent Past, Current & Future Analysis for Cutaneous and Systemic Leishmaniasis by Distribution Channel - Hospital Pharmacies, Retail Pharmacies, Drug Stores and Online Distribution Channel - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 396: Africa Historic Review for Cutaneous and Systemic Leishmaniasis by Distribution Channel - Hospital Pharmacies, Retail Pharmacies, Drug Stores and Online Distribution Channel Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
TABLE 397: Africa 16-Year Perspective for Cutaneous and Systemic Leishmaniasis by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacies, Retail Pharmacies, Drug Stores and Online Distribution Channel for the Years 2014, 2025 & 2030
TABLE 398: Africa Recent Past, Current & Future Analysis for Cutaneous and Systemic Leishmaniasis by Administration Route - Oral Route, Injectable Route and Topical Route - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 399: Africa Historic Review for Cutaneous and Systemic Leishmaniasis by Administration Route - Oral Route, Injectable Route and Topical Route Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
TABLE 400: Africa 16-Year Perspective for Cutaneous and Systemic Leishmaniasis by Administration Route - Percentage Breakdown of Value Sales for Oral Route, Injectable Route and Topical Route for the Years 2014, 2025 & 2030
TABLE 401: Africa Recent Past, Current & Future Analysis for Cutaneous and Systemic Leishmaniasis by Indication - Cutaneous Leishmaniasis Indication, Mucosal Leishmaniasis Indication and Visceral Leishmaniasis Indication - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
TABLE 402: Africa Historic Review for Cutaneous and Systemic Leishmaniasis by Indication - Cutaneous Leishmaniasis Indication, Mucosal Leishmaniasis Indication and Visceral Leishmaniasis Indication Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2014 through 2023 and % CAGR
TABLE 403: Africa 16-Year Perspective for Cutaneous and Systemic Leishmaniasis by Indication - Percentage Breakdown of Value Sales for Cutaneous Leishmaniasis Indication, Mucosal Leishmaniasis Indication and Visceral Leishmaniasis Indication for the Years 2014, 2025 & 2030
IV. COMPETITION
How Do Licenses Work?
Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.